Clinical data | |
---|---|
Other names | methyl(2-methyl-1-phenylpropan-2-yl)amine |
Routes of administration | IM/IV |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Rapidly demethylated in the body followed by hydroxylation. |
Excretion | Via urine (as unchanged and metabolites); more rapid in acidic urine. |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.002.638 |
Chemical and physical data | |
Formula | C11H17N |
Molar mass | 163.264 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Mephentermine (Wyamine, former brandname) is a cardiac stimulant.
It has been used as a treatment for low blood pressure.[1]
Mephentermine belongs to the class of adrenergic and dopaminergic cardiac stimulants excluding cardiac glycosides. Used in the treatment of heart failure.